论文部分内容阅读
[目的]研究肺心宝胶囊对肺源性心脏病缓解期临床疗效的影响。[方法]选择40例肺源性心脏病缓解期患者,随机分为两组,治疗组在西医常规治疗的基础上同时予肺心宝胶囊口服,对照组予西医常规治疗。治疗1个疗程后,观察比较两组的临床疗效和两组治疗前后临床症状和体征、免疫学、营养学等指标的变化。[结果]两组治疗后总有效率比较,治疗组优于对照组,差异有显著性意义(P<0.05);两组治疗后显效率比较,治疗组优于对照组,差异有高度显著性意义(P<0.01)。两组经治疗后免疫学指标均有明显改善,而治疗组与对照组比较除IgM外,其余各项指标均有显著性意义(P<0.05)。两组间营养学指标治疗后比较(P<0.01),提示治疗组营养学指标疗效优于对照组。[结论]肺心宝胶囊对提高机体免疫功能,改善营养状态有一定的疗效。可以改善肺源性心脏病缓解期患者的免疫功能,从而提高了对肺源性心脏病缓解期患者的临床疗效,提高了患者的生活质量和生存期。是治疗肺心病缓解期的有效药物。
[Objective] To study the effect of Feixin Capsule on the clinical effect of remission of pulmonary heart disease. [Methods] Forty patients with remission of pulmonary heart disease were selected and randomly divided into two groups. The treatment group was given oral administration of “Fei Xin Bao” capsule on the basis of routine treatment of Western medicine, while the control group was given routine treatment of Western medicine. After a course of treatment, the clinical curative effects of the two groups were observed and compared, and the changes of clinical symptoms and signs, immunology and nutrition before and after treatment were compared between the two groups. [Results] The total effective rate of the two groups after treatment was better than that of the control group, the difference was significant (P <0.05). The effective rate of the two groups after treatment was better than that of the control group, the difference was highly significant Significance (P <0.01). The immunological parameters of both groups were significantly improved after treatment, while the treatment group and the control group in addition to IgM, the remaining indicators were significant (P <0.05). Nutritional indicators between the two groups after treatment (P <0.01), suggesting that the treatment group nutritional index better than the control group. [Conclusion] Feixinbao Capsule has certain curative effect on improving immune function and improving nutritional status. Can improve the immune function of patients with remission of pulmonary heart disease, thereby improving the clinical efficacy of patients with remission of pulmonary heart disease and improve the quality of life and survival of patients. It is an effective medicine for remission of pulmonary heart disease.